Stroke costs are predicted to rise in low-and middleincome countries 1, 2 . This forecast is based on the increase in prevalence rates and the costs of new cerebral reperfusion interventions for the treatment of ischemic stroke (IS) 1, 2 . Despite most strokes occurring in low-and middle-income countries, there is limited information about the costs of stroke treatments in these settings 3 . For instance, only one retrospective study has reported the public costs of stroke in Brazil 4 , and this was conducted before IS cerebral reperfusion treatment was available.
The incidence of all strokes decreased by 37% in Joinville from 1995 to 2013; however, the one-year prevalence of functional dependency from 2005-2006 (n = 759) to 2012-2013 (n = 922) showed a nonsignificant increase of 32% for IS and a nonsignificant increase of 66% for primary intracerebral hemorrhage (PIH) 5 .
After 2014, the results of interventional studies showed that cerebral reperfusion for IS opened up new perspectives for IS prognosis 6 . In Brazil, the state-run health care system is universal. Three quarters of the population use it exclusively and one quarter uses both public and private health services 7 . However, the costs of these treatment options from the private sector in low-and middle-income countries, where health budgets are tight, remains unknown. We aimed to measure private in-hospital costs of IS (with and without cerebral reperfusion), primary intracerebral hemorrhage (PIH), subarachnoid hemorrhage (SAH) and transient ischemic attack (TIA) in Joinville, Brazil.
METHODS

Study design
This was a prospective bottom-up, one-year prevalencebased cost-of-illness study 8 . Data were extracted from two private hospitals (neither hospital has a stroke or neurocritical care unit), in the city of Joinville, Brazil, from September 1, 2016 to August 30, 2017. We included first-ever or recurrent IS, PIH, SAH or TIA in patients who were aged ≥18 years old, consecutively admitted over the study period. Patients were excluded if they had incomplete medical records, if they had been transferred from another hospital or if their hospitalization time exceeded the deadline for data collection.
Data collection
The principal investigator (LGDRV) used a questionnaire ( Figure 1 ) to register all checklist items from admission until hospital discharge in each patient. Admission date, final stroke diagnosis, hospitalization units, diagnostic work-up, medication, equipment, medical rounds, medical and nursing procedures, types of food, multidisciplinary rehabilitation sessions and clinical complications were extracted from the patient's medical records. Demographic information, socioeconomic status, cardiovascular risk factors and 30-day functional outcomes were extracted from the Joinville Stroke Registry 5 . The routine for stroke investigation followed the guidelines issued by the Brazilian Society of Cerebrovascular Diseases 9,10,11 (Table 1 ). The severity of IS was stratified according to the National Institute of Health Stroke Scale (NIHSS), with 0-3 being minor, 4-10 being moderate and 10 being severe 12 .
Data analysis
Collected data were compared with the patient's final hospital bill. The findings were discussed with the hospital's management centre if any divergence was identified. Together, the two hospitals serve 27 health plans, each with differences in their costs and fees criteria. Both hospitals use a mixture of methods to compute costs, which results in methodological differences in the allocation of costs ( Figure 2) . Therefore, to equate the methodological differences, the medical and nonmedical costs were split into 12 distinct subitems: 1) hospital daily: all hospital services including nursing services, private or semiprivate rooms, nutritionists, psychologists, pharmacy and kitchen staff, electrical power and water consumption, garbage collection, depreciation of equipment, cleaning and laundry; 2) emergency room rate: salaries of emergency room personnel, laundry, maintenance of equipment, electricity and water; 3) medical visits: daily medical and on-call visits; 4) medical procedures: material costs, medical fees and operating room fees, including all staff wages, electricity, water, maintenance and equipment depreciation; 5) rehabilitation team: daily visits from speech therapists, physiotherapists and occupational therapists; 6) equipment for procedures: needles, syringes, gauze, suction probes etc.; 7) medications: drugs and intravenous (IV) solutions; 8) laboratory tests: wages (biochemists, technicians and administrative assistants), tests, electric power, water, equipment maintenance and depreciation; 9) diagnostic work-up sections: medical reports and technical staff, materials, electric power, water, equipment maintenance and depreciation; 10) special feeding: enteral diet and special supplements (which are calculated separately from the hospital daily costs), unit value of the diet per bottle and supplement used and materials and equipment for administration; 11) medical gases: daily rate of gas consumption and 12) administrative fees: wages and uniforms of clerks, security staff, computer teams, receptionists and other administrative departments.
All personnel wages included the wage itself plus social and labor charges. Nonmedical costs were obtained by apportionment; for instance, the cost of employee labor was the sum of the average annual labor, the costs of training and uniforms divided by the number of sector beds. These apportions were present when calculating the fraction of electric power consumption, maintenance and depreciation of equipment in all sectors, as well as when calculating the cost of labor (wages) rehabilitation (e.g. in the case of professionals employed by the hospital, excluding outsourced services).
We determined the unit costs as the mean cost of each item per patient in the hospital stay and diagnostic work-up, including medical and nonmedical items.
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Statistical analysis
We evaluated differences among patient subgroups by using a χ 2 test, t test, or Mann-Whitney U test as appropriate. All tests were two tailed. Cost data were converted to 2016 currency values using a web-based tool (CCEMG -EPPI-Centre Cost Converter) 13 . The cost was first converted into the current year cost for Brazil using the gross domestic product (GDP) deflator index. In the next step, this cost was converted into United States dollars (US$) ( for 2016) using conversion rates based on purchasing power parity (PPP) for the GDP (the Brazilian real PPP value for 2016 was 0.49) 13 . For comparison, the original costs of other studies were converted to 2016 values. All values were in US$. Tests were performed using Statistical Analysis System software (version 9.2) with PROC GENMOD (SAS Institute, Inc, Cary, NC). The study was approved by the ethics in research committees at the involved hospitals and the UNIVILLE-Joinville Region University (opinion number: 1.657.067).
RESULTS
A total of 173 patients were included in the study, of whom 76% (131/173) were diagnosed with IS, 6% (11/173) with PIH, 2% (4/173) with SAH and 16% (27/173) with a TIA. We excluded 11 patients who were transferred from other hospitals. The overall mean age of the cohort was 68 years (SD ± 15). The median NIHSS scores for IS were 2 (IQR: 1-5), for PIH were 5 (IQR: 4-12) and for SAH were 8 (IQR: 7-12). Of the 131 IS patients, 62% (81) had mild stroke (NIHSS: 0-3), 27% (35) had a moderate stroke (NIHSS: 4-10) and 11% (15) had a severe stroke (NIHSS: >10). The mean length of stay (LOS) for IS was 8 days (SD ± 7), for PIH was 15 days (SD±16), for SAH was 11 days (SD ± 5) and for TIA was 4 days (SD ± 2). The 30-day case-fatality rates were 36% (4/11) for PIH patients and 6% (8/131) for IS patients. There were no deaths in the TIA and SAH groups.
The median total cost of hospitalization per patient based on stroke type ranged from US$2,316 (IQR: 1,692-2,959) for TIA to US$28,928 (IQR: 12,424-48,037) for SAH patients (p < 0.0001). Table 2 shows the total in-hospital costs and the daily costs among all stroke types and TIA. The median and mean costs of seven cardioembolic IS due to atrial fibrillation were US$6,386 (IQR: 4,003-10,589) and US$9,505 (SD ± 7,612), respectively.
The following patients were admitted in the intensive care unit (ICU): 31/131 patients with IS, 8/11 patients with PIH, 4/4 patients with SAH and 1/27 patient with TIA (this patient was submitted to electrical cardioversion for atrial fibrillation). In patients with IS, those who stayed in ICU remained twice as long in hospital and had a mean cost six times higher than those who did not go to the ICU. For PIH patients, the mean cost was twice as high in patients who stayed in the ICU with similar LOS.
As expected, the cost of hospitalization increased with LOS. For IS, the median cost for up to seven days was US$2,639 (IQR: 2,017-3,274), which increased to US$4,743 (IQR: 3,609-8,687) for 7-14 days and US$29,499 (IQR: 19,628-38,952) for stays > 14 days. Figure 3 shows the significant linear correlation between IS cost and LOS (r = 0.67; p < 0.001). Table 3 shows the cost per stroke type stratified by weeks of hospital stay. Also as expected, the IS costs grew according to clinical severity when arriving at hospital (Figure 4) . The costs were US$3,370 (IQR: 2,418-4,718) for the 81 mild IS patients (NIHSS: 0-3), US$4,335 (IQR: 3,297-8,599) for the 35 moderate IS patients (NIHSS: 4-10) and US$30,753 (IQR: 21,751-38,973) for the 15 severe IS patients (NIHSS: >10; p < 0.0001).
The IS cost was also stratified with and without reperfusion ( Figure 5 ). Intra-arterial (IA) thrombectomy increased the cost of IS treatment 10-11-fold compared to IV thrombolysis (p < 0.0001). A total of 117 IS patients did not receive cerebral reperfusion, and the median cost for each patient was US$3,539 (IQR: 2,647-5,771). Conversely, six patients received IV thrombolysis, and the median cost each patient was US$11,463 (IQR: 8,931-14,291). In addition, eight patients received IV thrombolysis and IA thrombectomy, and the median cost for each patient was US$37,948 (IQR: 32,697-47,205).
The proportions of costs were calculated among all strokes types and TIA. These included daily costs, emergency room rates, medications, materials, laboratory investigations, medical procedures, medical fees, diagnostic work-ups, multidisciplinary teams, special nutrition, medical gases and administrative fees ( Figure 6 ). Table 4 shows the unit costs of each item and the average cost per stroke type in 2016-2017.
Hospital stay had the greatest impact on total cost in IS, PIH and TIA (representing 24% to 32% of the total cost). Hospital stay costs for intensive care and nursing comprised 26% of all final bills (US$474,602 to US$1,845,927). In the SAH group, the greatest impact was from medical procedures (44%). This was also the item with the second greatest impact on final cost in IS patients (18%). These procedures comprised 15% of the total final bill (US $274,736/US$1,845,927). Intra-arterial thrombectomies (solitaire stent, for anterior circulation 8F Corail balloon-guided catheter (Balt) and for posterior circulation 6F Chaperon catheter) were performed in 6% of all patients (8/131) and comprised 7% of the total final bill (US$130,467/US$1,845,927). Therefore, more than one-third of all medical and nonmedical costs were incurred by two items.
DISCUSSION
This prospective study in a middle-income country showed that the overall in-hospital cost of 173 strokes during 2016-17 was approximately US$1.8 million. The average cost per patient was US$10,404. As expected, IS was the most common type of stroke (76%). The cost of IS treatment was greater in patients who had a more severe stroke and in those submitted to IV thrombolysis and IA thrombectomy. Overall, the IS costs were approximately US$3,500 for those without cerebral reperfusion, US$11,500 for those receiving IV thrombolysis and US$38,000 for those receiving IV and IA cerebral reperfusion. To compare these findings, the values from the original studies were adjusted to the PPP for the GDP in 2016. Therefore, the median IS costs (without cerebral reperfusion) in this study were higher than in a public hospital in São Paulo in 2009 (US$2,166) 4 but lower than private costs in India (US $3,720) in 2013 14 , Japan (US$6,640) in 2003 15 and the Netherlands in 2015 (US$7,496) 16 . The costs for IV or combined cerebral reperfusion treatment for IS were similar to those of studies conducted in the USA; for instance, the median hospital costs for 63,472 IS patients who received IV thrombolysis from 2001 to 2008 in the USA was US$15,751 (IQR: 11,155-23,253) 17 . Studies in the USA have recently reported even higher costs; for example, costs ranged from US$24,817 to US$33,810 for IV thrombolysis, and from US$39,825 to US$40,743 for IV and IA thrombolysis 18 . In the latter study, the clinical severity of patients submitted to IV thrombolysis was greater than that in this study, whereas the patients receiving IA and IV reperfusion had clinical severities costs that were similar to those in this study.
As in other studies, LOS and clinical severity were directly related to the final hospital costs 19, 20 . The LOS in this study was approximately 11 days for a major stroke and four days for a TIA. The LOS for IS (eight days) was shorter than for patients in Japan (33 days) 15 , China (20 days) 19 and Brazil (13 days) 4 but similar to patients in the Netherlands (seven days) 16 and Malaysia (six days) 21 . These differences were attributed to two main factors: 1) other studies with a higher LOS 15, 19 included patients with a higher clinical severity at hospital admission, and 2) the characteristics of the hospitals were different in China (secondary and tertiary hospitals); treatment of the acute and rehabilitation phase was performed in Japan; the other Brazilian study was carried out in a public hospital.
The median costs of PIH in this study was US$16,442, which was higher than the costs reported in 2009 in São Paulo (US$4,670) in public hospitals 4 . A cohort study in Canada reported that the median cost of hospital care for 987 PIH patients was US$11,777 per patient 22 . The PIH costs in this study were higher than in Malaysia (US$3,012) 21 and China (US$4,934) 19 .
Subarachnoid hemorrhage was the most expensive of all stroke types. The median SAH cost in this study was US$28,928, which was similar to Germany (US$24,091) 23 but lower than Singapore (US$38,633) 24 . Again, all costs were lower than in the USA, where the median cost for hospitalization of clipped and coiled patients was US$77,462 and US$74,041, respectively, in 2008 25 . The sample of patients with SAH in this study was very small (n = 4), thus making it difficult to compare the results with those reported in the literature.
The median cost of a TIA in this study was US$2,316 and the mean LOS was four days. In the Netherlands, the LOS was the same, but the costs were higher (US$3,474) 16 . In the USA, the LOS was also the same but the costs were even higher (US$16,450) 26 . In this USA study, the author reported that the treatment of TIA comorbidities, the characteristics of hospitals and health insurance increased the LOS and cost of hospitalization.
This study has some limitations. For example, the absence of a standard methodology for computing the costs of two hospital entities made it necessary to create a method for the appropriation and allocation of costs; the sample for SAH, PIH and TIA were small; the two general and private hospitals did not have stroke units; the hospitals cared for patients from 27 different health plans and variations were found in the price tables of the inputs and the profit of private entities was included in the final costs. The strength of this study includes its prospective design, which included all medical and nonmedical costs for all stroke types and TIAs from a private-sector setting. To compare the findings with costs in other private hospitals, the costs of the original studies were adjusted to the GDP Deflator Index and PPP in 2016 13 .
In conclusion, stroke is a costly disease that is directly associated with the length of hospital stay and clinical severity. The costs of PIH and SAH were more expensive than IS. When only hospital costs were considered, IV cerebral reperfusion for IS was three times more expensive than conservative treatments, whereas combined treatments were 11 times more expensive. The costs associated with greater stroke severity and disability in eligible IS patients not treated with reperfusion therapies were not calculated. In high-income countries, the cost-effectiveness of cerebral reperfusion for IS has been defined, 27, 28 however, in Brazil, only one retrospective study has shown that the use of thrombolysis in IS patients changes the natural history of the disease and, moreover, that the intervention contributes to the reduction of direct (hospitalization and rehabilitation) and indirect (loss of productivity) costs 29 . It is highly likely that thrombectomy is also cost-effective in developing countries.
